Acute Promyelocytic Leukemia Clinical Trial
Official title:
A Phase I Trial of Tamibarotene and Arsenic Trioxide for the Treatment of Relapsed Acute Promyelocytic Leukemia
Subjects have acute promyelocytic leukemia (APL) that has come back (relapsed) after initial treatment or has not gone away with initial therapy. This research study involves testing an investigational drug called Tamibarotene in combination with standard treatment for relapsed APL called arsenic trioxide. Tamibarotene has been approved in Japan to treat patients with relapsed APL since April 2005. Tamibarotene is in the same family of drugs as all-trans retinoic acid (ATRA), a medication that subjects received previously in their treatment. ATRA and tamibarotene both cause the APL cells to differentiate (or become) normal non-leukemia cells. Laboratory studies of tamibarotene have shown to be effective in APL. The purpose of this study is to determine if tamibarotene in combination with arsenic trioxide is safe and effective.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00520208 -
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
|
Phase 2 | |
Suspended |
NCT04996030 -
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT02899169 -
Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
|
Phase 3 | |
Terminated |
NCT00852709 -
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
|
Phase 1 | |
Recruiting |
NCT04793919 -
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
|
Phase 2 | |
Recruiting |
NCT02938858 -
French Registry of First-line Treatment of Acute Promyelocytic Leukemia
|
N/A | |
Recruiting |
NCT02991066 -
Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia
|
||
Withdrawn |
NCT00670150 -
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
|
Phase 2 | |
Recruiting |
NCT01064570 -
AIDA 2000 Guidelines
|
Phase 2 | |
Completed |
NCT01472107 -
Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy
|
||
Active, not recruiting |
NCT03096496 -
Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy
|
||
Completed |
NCT00465933 -
Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)
|
Phase 4 | |
Active, not recruiting |
NCT02688140 -
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
|
Phase 3 | |
Active, not recruiting |
NCT01987297 -
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
|
Phase 4 | |
Terminated |
NCT00907582 -
ASCT for Relapsed APL After Molecular Remission
|
Phase 2 | |
Recruiting |
NCT00517712 -
Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia
|
Phase 2/Phase 3 | |
Completed |
NCT01902329 -
A Safety Study of SGN-CD33A in AML Patients
|
Phase 1 | |
Completed |
NCT01404949 -
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
|
Phase 2 | |
Completed |
NCT00504764 -
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
|
Phase 4 | |
Completed |
NCT00408278 -
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
|
Phase 4 |